Supplementary Online Content

Evron JM, Hummel SL, Reyes-Gastelum D, Haymart MR, Banerjee M, Papaleontiou M. Association of thyroid hormone treatment intensity with cardiovascular mortality among US veterans. *JAMA Netw Open.* 2022;5(5):e2211863. doi:10.1001/jamanetworkopen.2022.11863

eTable 1. Frequency Distributions of the Number of Thyrotropin and Free Thyroxine Measurements
eFigure 1. Mean Number of Thyrotropin Measurements per Patient, by Year
eFigure 2. Mean Number of Free Thyroxine Measurements per Patient, by Year
eTable 2. Characteristics of Patients on Thyroid Hormone Therapy Associated With Cardiovascular Mortality (Age as a Continuous Variable)

This supplementary material has been provided by the authors to give readers additional information about their work.
### eTable 1. Frequency Distributions of the Number of Thyrotropin and Free Thyroxine Measurements

| Year   | Thyrotropin | Free Thyroxine |
|--------|-------------|----------------|
| 2004   | 50,714      | 14,886         |
| 2005   | 80,961      | 22,797         |
| 2006   | 89,750      | 25,594         |
| 2007   | 92,083      | 26,993         |
| 2008   | 95,120      | 29,174         |
| 2009   | 99,227      | 30,714         |
| 2010   | 103,940     | 31,905         |
| 2011   | 107,376     | 34,471         |
| 2012   | 112,290     | 37,457         |
| 2013   | 116,079     | 39,544         |
| 2014   | 123,807     | 43,457         |
| 2015   | 134,730     | 51,976         |
| 2016   | 165,679     | 65,428         |
| 2017   | 388,385     | 131,533        |
eFigure 1. Mean Number of Thyrotropin Measurements per Patient, by Year
eFigure 2. Mean Number of Free Thyroxine Measurements per Patient, by Year
**Table 2.** Characteristics of Patients on Thyroid Hormone Therapy Associated With Cardiovascular Mortality (Age as a Continuous Variable)

| Thyrotropin Cohort | Free Thyroxine Cohort |
|-------------------|-----------------------|
| **Patient Characteristics** | **Adjusted Hazard Ratio (95%CI)** | **Patient Characteristics** | **Adjusted Hazard Ratio (95%CI)** |
| Thyrotropin (annual geometric mean) | Free Thyroxine (annual arithmetic mean) | | |
| < 0.1 | 1.42 (1.34–1.50) | <0.7 | 1.59 (1.53–1.66) |
| 0.1 – <0.5 | 1.14 (1.10–1.18) | 0.7–1.9 | 1 [Reference] |
| 0.5 – 5.5 | 1 [Reference] | >1.9 | 1.29 (1.19–1.40) |
| >5.5 – <7.5 | 1.41 (1.38–1.45) | | |
| 7.5 – <10 | 1.76 (1.70–1.83) | | |
| 10 – 20 | 2.16 (2.08–2.24) | | |
| > 20 | 2.75 (2.62–2.88) | | |
| Sex | Sex | | |
| Male | 1 [Reference] | Male | 1 [Reference] |
| Female | 0.77 (0.69–0.75) | Female | 0.68 (0.64–0.72) |
| Age (years) | 1.08 (1.08–1.08) | Age (years) | 1.08 (1.08–1.08) |
| Race | Race | | |
| White | 1 [Reference] | White | 1 [Reference] |
| Black | 0.99 (0.96–1.03) | Black | 0.96 (0.92–1.01) |
| Other | 0.91 (0.86–0.97) | Other | 0.99 (0.91–1.07) |
| Unknown | 1.33 (1.29–1.36) | Unknown | 1.35 (1.30–1.41) |
| Ethnicity | Ethnicity | | |
| Not Hispanic | 1 [Reference] | Not Hispanic | 1 [Reference] |
| Hispanic | 0.65 (0.62–0.68) | Hispanic | 0.65 (0.62–0.69) |
| Unknown | 1.74 (1.69–1.78) | Unknown | 1.64 (1.57–1.71) |
| Smoking | Smoking | | |
| Never | 1 [Reference] | Never | 1 [Reference] |
| Current/Former | 1.22 (1.19–1.25) | Current/Former | 1.22 (1.19–1.26) |
| Unknown | 1.51 (1.47–1.54) | Unknown | 1.42 (1.37–1.47) |
| Hypertension | 1.55 (1.50–1.59) | Hypertension | 1.67 (1.60–1.74) |
| Hyperlipidemia | 0.93 (0.91–0.95) | Hyperlipidemia | 0.96 (0.93–0.99) |
| Diabetes mellitus | 1.42 (1.40–1.44) | Diabetes mellitus | 1.42 (1.38–1.45) |
| Prior history of cardiovascular disease | 1.39 (1.37–1.42) | Prior history of cardiovascular disease | 1.46 (1.42–1.49) |
| Prior history of cardiac arrhythmia | 1.92 (1.89–1.95) | Prior history of cardiac arrhythmia | 2.02 (1.98–2.07) |

*The category “Other” is composed of the following races: Asian, Native Hawaiian or Pacific Islander, Alaska Native or American Indian, and multiracial. Units: mIU/L (thyrotropin), ng/dL (free thyroxine). © 2022 Evron JM et al. JAMA Network Open.*